Background: In the last three decades, West Nile virus (WNV, Flaviviridae, Orthoflavivirus genus) has become one of the most important encephalitic agents worldwide, causing substantial numbers of cases in humans and horses every year by re-emerging in endemic areas and emerging in new territories. It is considered that after natural WNV infection, humans and birds develop long-term immunoprotection, but data on immunoprotection in horses is scarce. Hypothesis: West Nile virus infection provides long-term humoral immunity in subclinically infected horses. Animals: Client-owned, naturally WNV subclinically infected non-WNV-vaccinated, healthy horses. Methods: In this prospective cohort study, anti-WNV neutralizing antibody (nAb) titers of 25 horses were monitored for 5 consecutive years in Hungary. Serum samples were collected annually. First, a WNV immunoglobulin G (IgG) ELISA was performed, followed by virus neutralization tests (VNT) for endemic orthoflaviviruses. A VNT titer > 8 was considered positive. Results: The mean WNV titer of horses was 260.64 ± 336.74 in 2019, 114.32 ± 107.36 in 2020, 95.38 ± 115.56 in 2021, 22.53 ± 25.71 in 2022 and 6.31 ± 5.15 in 2023. A significant decrease (p < 0.001) in the nAb titers occurred over time. In 2023, 88% of the horses had WNV VNT titers below the cut-off value. Conclusion and Clinical Relevance: Our results showed a significant decrease in WNV titers over time. Because nAbs correlate best with orthoflavivirus protection, our findings suggest that horses might not be protected against re-infection. We recommend regular nAb titer testing or vaccination in endemic areas.
West Nile virus (WNV) is a mosquito-borne neurotropic virus that causes neurologic disease in both humans and horses. Yet the long-term cellular immune response following natural infection in horses remains poorly understood. This study aims to evaluate the WNV-specific T-cell response in horses recovered from West Nile neuroinvasive disease (WNND). Twelve client-owned horses (4 Hungarian sport horses, 2 Lippizaners, 1 KWPN, 1 Shagya Arabian, 1 Friesian, 1 Gidran, 1 Andalusian, and 1 draft cross horse) with confirmed clinical WNV infection were enrolled, and peripheral blood mononuclear cells (PBMCs) were collected approximately 290 days post infection. An equine interferon-gamma (IFNγ) Enzyme-Linked Immunospot (ELISpot) assay was performed using a WNV capsid peptide pool as an antigen to assess virus-specific cellular immunity. Results: Ten of twelve horses (83%) exhibited a significant IFNγ response. Statistical analyses revealed no association between ELISpot responses and clinical severity, age, sex, breed, or neutralizing antibody titers. These results demonstrate that naturally infected horses are capable of mounting robust WNV-specific T-cell responses independent of humoral immunity. The findings support a potentially important role for cellular immune memory in long-term protection against WNV reinfection and suggest that the capsid peptide-based ELISpot assay may serve as a useful diagnostic or research tool for the evaluation of orthoflavivirus immunity in equines.